利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

38 条记录 (耗时 0.054 秒)

    CLOSTRIDIAL TOXIN DERIVATIVES ABLE TO MODIFY PERIPHERAL SENSORY AFFERENT FUNCTIONS
    32.
    发明申请
    CLOSTRIDIAL TOXIN DERIVATIVES ABLE TO MODIFY PERIPHERAL SENSORY AFFERENT FUNCTIONS 审中-公开
    外用毒素衍生物可修改外周感觉功能

    公开(公告)号：US20120141511A1

    公开(公告)日：2012-06-07

    申请号：US13270662

    申请日：2011-10-11

    申请人： Keith Alan Foster ,  Michael John Duggan ,  Clifford Charles Shone

    发明人： Keith Alan Foster ,  Michael John Duggan ,  Clifford Charles Shone

    IPC分类号： A61K39/385 ,  C12P21/06 ,  A61K39/395 ,  A61P25/00 ,  C07K19/00 ,  C07K17/02

    CPC分类号： C07K14/48 ,  A61K38/4886 ,  A61K38/4893 ,  A61K47/62 ,  C07K14/33 ,  C07K2319/00 ,  Y10S424/832

    摘要： A novel agent for the targeted control of a mammalian cell activity can be used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E, linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain, which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome; Domain T is the Translocation Domain, which translocates the agent from within the endosome across the endosomal membrane into the cytosol of the cell; and Domain E is the Effector Domain, which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell.

    摘要翻译： 用于靶向控制哺乳动物细胞活性的新型药剂可用于控制特定细胞类型与其外部环境的相互作用。 该试剂具有用作治疗各种疾病的药物的应用。 根据本发明的试剂包括以下列方式连接在一起的三个B区，T区和E区：域B域T域E，其中域B是结合域，其结合试剂到细胞上的结合位点 经历内吞以产生内体; 域T是易位结构域，其将来自内体的试剂从内体膜转移到细胞的胞质溶胶中; 并且E区是效应域，其抑制可循环膜囊泡将整合膜蛋白转运到细胞表面的能力。

    Clostridial toxin derivatives able to modify peripheral sensory afferent functions
    33.
    发明授权
    Clostridial toxin derivatives able to modify peripheral sensory afferent functions 失效
    能够修饰周围感觉传入功能的梭菌毒素衍生物

    公开(公告)号：US07892560B2

    公开(公告)日：2011-02-22

    申请号：US11819648

    申请日：2007-06-28

    申请人： Keith Alan Foster ,  Michael John Duggan ,  Clifford Charles Shone

    发明人： Keith Alan Foster ,  Michael John Duggan ,  Clifford Charles Shone

    IPC分类号： A61K38/16 ,  A61K38/18 ,  C07K14/33 ,  C07K14/485

    CPC分类号： C07K14/48 ,  A61K38/4886 ,  A61K38/4893 ,  A61K47/62 ,  C07K14/33 ,  C07K2319/00 ,  Y10S424/832

    摘要： This invention describes a novel agent for the targeted control of a mammalian cell activity, in particular the agent is used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome, Domain T is the Translocation Domain which translocates the agent (with or without the Binding Site) from within the endosome across the endosomal membrane into the cytosol of the cell, Domain E is the Effector Domain which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell.

    摘要翻译： 本发明描述了用于靶向控制哺乳动物细胞活性的新型试剂，特别是该试剂用于控制特定细胞类型与其外部环境的相互作用。 该试剂具有用作治疗各种疾病的药物的应用。 根据本发明的药剂包含以下列方式连接在一起的三个B，T和E域：域B结构域T域E，其中B区是绑定结构域，该结合域将该试剂结合到经历内吞作用的细胞上的结合位点 为了产生一个内体，结构域T是易位区域，它将试剂（有或者没有结合位点）从内体内穿过内体膜转移到细胞的细胞溶质中，E区是抑制 可循环膜囊将整体膜蛋白转运至细胞表面。

    TREATMENT OF MUCUS HYPERSECRETION
    34.
    发明申请
    TREATMENT OF MUCUS HYPERSECRETION 审中-公开
    治疗妊娠高血压

    公开(公告)号：US20080249019A1

    公开(公告)日：2008-10-09

    申请号：US12101749

    申请日：2008-04-11

    申请人： Keith Alan Foster ,  John Chaddock

    发明人： Keith Alan Foster ,  John Chaddock

    IPC分类号： A61K38/02 ,  A61P11/06 ,  A61P11/16

    CPC分类号： C07K14/33 ,  A61K38/00 ,  C07K2319/33 ,  Y02A50/471 ,  Y02A50/473

    摘要： A polypeptide and a nucleic acid encoding the polypeptide are described. The polypeptide includes a cytotoxic toxin, a targeting domain that selectively binds to a target cell that is a mucus-secreting cell and a translocating domain that translocates the cytotoxic toxin into the target cell. A nucleic acid encoding the polypeptide is also described. Also described is a pharmaceutical composition for topical administration to a patient suffering from mucus hypersecretion which includes the polypeptide and a formulation component selected from the group consisting of an excipient, an adjuvant and a propellant. Methods of treating hypersecretion of mucus, chronic obstructive pulmonary disease (COPD) or asthma are also described. These methods include administering to a patient in need thereof a therapeutically effective amount of the polypeptide.

    摘要翻译： 描述了编码多肽的多肽和核酸。 该多肽包括细胞毒素毒素，靶向结构域，其选择性地结合靶分泌细胞，其是分泌粘液的细胞，以及将细胞毒性毒素转移到靶细胞中的易位结构域。 还描述了编码该多肽的核酸。 还描述了一种用于局部给予患有粘液分泌过高的患者的药物组合物，其包括多肽和选自赋形剂，佐剂和推进剂的制剂成分。 还描述了治疗粘液分泌过多，慢性阻塞性肺疾病（COPD）或哮喘的方法。 这些方法包括向有需要的患者施用治疗有效量的多肽。

    Preparation of highly pure toxin fragments
    36.
    发明授权
    Preparation of highly pure toxin fragments 有权
    制备高纯度毒素片段

    公开(公告)号：US07193066B1

    公开(公告)日：2007-03-20

    申请号：US10070764

    申请日：2000-09-13

    申请人： John Andrew Chaddock ,  Frances Celine Gail Alexander ,  Keith Alan Foster

    发明人： John Andrew Chaddock ,  Frances Celine Gail Alexander ,  Keith Alan Foster

    IPC分类号： C07K1/00 ,  G01N33/537 ,  G01N33/549

    CPC分类号： C07K16/1282 ,  A61K38/164 ,  C07K14/33 ,  Y10S530/81 ,  Y10S530/811 ,  A61K2300/00

    摘要： Toxin derivatives are prepared by proteolytic treatment of holotoxin, and their toxicity is reduced by contacting the preparation with a ligand, which can be a metal or an antibody or another ligand. This ligand selectively binds to the toxin but not to the toxin derivative. Removing the ligand and toxin bound to the ligand further reduces toxicity. A second ligand is used to remove conjugates of the toxin and the first ligand. Compositions contain the purified derivative, optionally plus the toxin and the ligand.

    摘要翻译： 通过蛋白水解处理全毒素制备毒素衍生物，并且通过使制剂与可以是金属或抗体或另一种配体的配体接触来降低它们的毒性。 该配体选择性地结合毒素，但不与毒素衍生物结合。 去除与配体结合的配体和毒素进一步降低毒性。 第二配体用于去除毒素和第一配体的缀合物。 组合物含有纯化的衍生物，任选加上毒素和配体。

    MODIFIED NON-CYTOTOXIC PROTEASES
    38.
    发明申请
    MODIFIED NON-CYTOTOXIC PROTEASES 有权
    改良的非细胞毒素

    公开(公告)号：US20120128649A1

    公开(公告)日：2012-05-24

    申请号：US13202696

    申请日：2009-12-16

    申请人： John Andrew Chaddock ,  Keith Alan Foster

    发明人： John Andrew Chaddock ,  Keith Alan Foster

    IPC分类号： C12N9/96 ,  A61K8/66 ,  A61P21/00 ,  C07H21/04 ,  A61K38/48

    CPC分类号： A61K38/4893 ,  A61K38/00 ,  C07K2319/06 ,  C07K2319/33 ,  C07K2319/50 ,  C12N9/50 ,  C12N9/52 ,  C12Y304/24069

    摘要： The present invention relates to a modified polypeptide comprising a non-cytotoxic protease, a translocation domain, a destructive protease cleavage site and a Targeting Moiety that binds to a Binding Site on a nerve cell, wherein after cleavage of the destructive cleavage site the polypeptide has reduced potency. The destructive cleavage site is recognised and cleaved by a protease present at or in an off-site target cell, and, in one embodiment, the polypeptide is a modified clostridial neurotoxin. The present invention also relates to the use of said polypeptides for treating a range of conditions, and to nucleic acids encoding said polypeptides.

    摘要翻译： 本发明涉及包含非细胞毒性蛋白酶，易位结构域，破坏性蛋白酶切割位点和与神经细胞上的结合位点结合的靶向部位的修饰多肽，其中在所述破坏性切割位点切割后，所述多肽具有 功效降低 破坏性切割位点被存在于位点外靶点细胞上或位于外部靶细胞中的蛋白酶识别和切割，并且在一个实施方案中，多肽是经修饰的梭菌神经毒素。 本发明还涉及所述多肽用于治疗一系列病症的用途，以及编码所述多肽的核酸。